MX2022000128A - Desarrollo de clasificadores para estratificar pacientes. - Google Patents

Desarrollo de clasificadores para estratificar pacientes.

Info

Publication number
MX2022000128A
MX2022000128A MX2022000128A MX2022000128A MX2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A MX 2022000128 A MX2022000128 A MX 2022000128A
Authority
MX
Mexico
Prior art keywords
responsive
classifiers
development
subjects
stratify patients
Prior art date
Application number
MX2022000128A
Other languages
English (en)
Spanish (es)
Inventor
Susan Ghiassian
Theodore R Mellors
Marc Santolini
Asher Ameli
Nancy Schoenbrunner
Viatcheslav R Akmaev
Keith J Johnson
Original Assignee
Scipher Medicine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipher Medicine Corp filed Critical Scipher Medicine Corp
Publication of MX2022000128A publication Critical patent/MX2022000128A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
MX2022000128A 2019-06-27 2020-06-26 Desarrollo de clasificadores para estratificar pacientes. MX2022000128A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962867853P 2019-06-27 2019-06-27
US201962882402P 2019-08-02 2019-08-02
US202062965486P 2020-01-24 2020-01-24
PCT/US2020/039991 WO2020264426A1 (en) 2019-06-27 2020-06-26 Developing classifiers for stratifying patients

Publications (1)

Publication Number Publication Date
MX2022000128A true MX2022000128A (es) 2022-04-27

Family

ID=74061318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000128A MX2022000128A (es) 2019-06-27 2020-06-26 Desarrollo de clasificadores para estratificar pacientes.

Country Status (11)

Country Link
US (5) US11195595B2 (enExample)
EP (1) EP3990656B1 (enExample)
JP (1) JP2022541125A (enExample)
KR (1) KR20220044720A (enExample)
CN (1) CN114402084A (enExample)
AU (1) AU2020308906A1 (enExample)
CA (1) CA3145237A1 (enExample)
GB (1) GB2603294A (enExample)
IL (1) IL289304A (enExample)
MX (1) MX2022000128A (enExample)
WO (1) WO2020264426A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178546A1 (en) 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
US12548678B2 (en) 2020-05-14 2026-02-10 Ampel Biosolutions, Llc Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus
JP2022541125A (ja) 2019-06-27 2022-09-22 サイファー メディシン コーポレーション 患者を層別化するための分類子の開発
WO2022051245A2 (en) * 2020-09-01 2022-03-10 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
US11430575B2 (en) * 2020-11-13 2022-08-30 Specialty Diagnostic (SDI) Laboratories, Inc. Systems and methods for a data driven disease test result prediction
US12271832B2 (en) * 2021-02-12 2025-04-08 Tempus Ai, Inc. Artificial intelligence engine for directed hypothesis generation and ranking
EP4308732A4 (en) * 2021-03-19 2025-02-26 Scipher Medicine Corporation METHODS FOR CLASSIFICATION AND TREATMENT OF PATIENTS
WO2022240875A1 (en) 2021-05-13 2022-11-17 Scipher Medicine Corporation Assessing responsiveness to therapy
US20220399092A1 (en) * 2021-06-10 2022-12-15 Rajant Health Inc. Ai-enabled health platform
EP4359567A4 (en) * 2021-06-22 2025-06-11 Scipher Medicine Corporation METHODS AND SYSTEMS FOR THERAPY MONITORING AND EXPERIMENTAL CONDUCT
WO2023150731A2 (en) * 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies
CN114861764B (zh) * 2022-04-11 2024-11-22 中国科学院计算技术研究所 基于auc优化的多类别分类方法及系统
CN115206439B (zh) * 2022-05-20 2025-07-18 南开大学 跨语言平台的空间转录组数据转换方法及系统
WO2024081737A1 (en) * 2022-10-12 2024-04-18 Exagen Inc. Biomarker selection for machine learning enabled prediction of treatment response
CN116312796B (zh) * 2022-12-27 2023-11-14 江苏先声医学诊断有限公司 一种基于期望最大化算法的宏基因组丰度估计方法及系统
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2026128869A1 (en) * 2024-12-12 2026-06-18 Palisade Bio, Inc. Companion diagnostic methods of administering pde4 inhibitors

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
EP2161348A1 (en) 2005-09-27 2010-03-10 Source MDX Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
SG182183A1 (en) 2007-06-08 2012-07-30 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US7863021B2 (en) 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009102957A2 (en) 2008-02-14 2009-08-20 The Johns Hopkins University Methods to connect gene set expression profiles to drug sensitivity
WO2009117791A2 (en) 2008-03-28 2009-10-01 Katholieke Universiteit Leuven Mucosal gene signatures
KR20100003759A (ko) 2008-07-02 2010-01-12 양혜지 반짝이가 포함된 구두약
JP2012500993A (ja) 2008-08-25 2012-01-12 ヤンセン バイオテツク，インコーポレーテツド 潰瘍性大腸炎及び関連した疾患における抗ｔｎｆ処置のためのバイオマーカー
US20110191087A1 (en) 2008-09-03 2011-08-04 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Computer implemented model of biological networks
CA2737485A1 (en) 2008-10-10 2010-04-15 Mount Sinai Hospital Methods for classifying samples based on network modularity
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
CA2777800C (en) 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
JP6073217B2 (ja) 2010-04-29 2017-02-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ゲノムモデルに関するデータ統合を用いたパスウェイ認識アルゴリズム（ｐａｒａｄｉｇｍ）
US10192641B2 (en) 2010-04-29 2019-01-29 The Regents Of The University Of California Method of generating a dynamic pathway map
WO2012066536A2 (en) 2010-11-16 2012-05-24 Prediguard Transcriptome signatures discriminate etanercept-treated rheumatoid arthritis (ra) patients according to their response or refractory status
EP2668287B1 (en) 2011-01-25 2017-09-06 TC LAND Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody
US20130040835A1 (en) 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
US9416190B2 (en) 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
HU230680B1 (hu) 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
DK2914739T3 (da) 2012-11-05 2017-11-27 Novigenix Sa Kombinationer af biomarkører for kolorektale tumorer
CA2892490A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US10161936B2 (en) 2013-03-08 2018-12-25 University Of Leipzig Method and kit for cytokine analysis from a human whole blood sample
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015006213A1 (en) 2013-07-08 2015-01-15 Northeastern University Methods for identifying complex disease subtypes
US9387246B2 (en) 2013-09-03 2016-07-12 L. Douglas Graham Treatment methods for rheumatoid arthritis
WO2015084461A2 (en) 2013-09-23 2015-06-11 Northeastern University System and methods for disease module detection
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
CA2943821A1 (en) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
WO2015164406A1 (en) 2014-04-21 2015-10-29 University Of South Florida Salivary inflammatory biomarkers associated with glycemic control and oral health
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
JP2018504584A (ja) 2014-12-02 2018-02-15 ネステク ソシエテ アノニム 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法
HK1257443A1 (zh) * 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
EP3356561B1 (en) * 2015-10-02 2021-10-27 Momenta Pharmaceuticals, Inc. Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation
US10018637B2 (en) 2015-10-06 2018-07-10 Celgene International Ii Sarl Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast
ES2716900T3 (es) 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
US20190080051A1 (en) 2015-11-11 2019-03-14 Northeastern University Methods And Systems For Profiling Personalized Biomarker Expression Perturbations
US20170145501A1 (en) 2015-11-20 2017-05-25 Lasse Folkersen Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response
EP3440579A4 (en) 2015-11-24 2020-03-25 Klaritos, Inc. INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES
GB201521357D0 (en) 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
JP6572120B2 (ja) 2015-12-14 2019-09-04 浜松ホトニクス株式会社 光ビーム照射装置
WO2017151755A1 (en) 2016-03-02 2017-09-08 Crescendo Bioscience Biomarkers and methods for predicting response to discontinuation of inflammatory disease therapy
WO2017223116A2 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
EP3654993A4 (en) 2017-07-17 2021-08-25 The Broad Institute, Inc. CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
US20200165677A1 (en) 2017-07-18 2020-05-28 Thaddeus Stappenbeck Methods and uses of inflammatory bowel disease biomarkers
US10512775B2 (en) * 2017-08-30 2019-12-24 Cochlear Limited Noise reduction for implantable hearing prostheses
US20190287644A1 (en) 2018-02-15 2019-09-19 Northeastern University Correlation Method To Identify Relevant Genes For Personalized Treatment Of Complex Disease
WO2019178546A1 (en) 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
CA3119294A1 (en) 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of inflammatory bowel disease
WO2020198068A1 (en) 2019-03-22 2020-10-01 Inflammatix, Inc. Systems and methods for deriving and optimizing classifiers from multiple datasets
SG11202110655UA (en) 2019-03-28 2021-10-28 Phase Genomics Inc Systems and methods for karyotyping by sequencing
JP2022541125A (ja) 2019-06-27 2022-09-22 サイファー メディシン コーポレーション 患者を層別化するための分類子の開発
WO2022051245A2 (en) 2020-09-01 2022-03-10 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
EP4308732A4 (en) 2021-03-19 2025-02-26 Scipher Medicine Corporation METHODS FOR CLASSIFICATION AND TREATMENT OF PATIENTS
WO2023150731A2 (en) 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies

Also Published As

Publication number Publication date
US20220375541A1 (en) 2022-11-24
WO2020264426A1 (en) 2020-12-30
US12525318B2 (en) 2026-01-13
CN114402084A (zh) 2022-04-26
EP3990656C0 (en) 2026-04-22
US11783913B2 (en) 2023-10-10
GB202119148D0 (en) 2022-02-16
EP3990656A1 (en) 2022-05-04
US20240355416A1 (en) 2024-10-24
US20210280271A1 (en) 2021-09-09
US11456056B2 (en) 2022-09-27
US11195595B2 (en) 2021-12-07
US20230386606A1 (en) 2023-11-30
JP2022541125A (ja) 2022-09-22
US20220101946A1 (en) 2022-03-31
CA3145237A1 (en) 2020-12-30
IL289304A (en) 2022-02-01
KR20220044720A (ko) 2022-04-11
US12062415B2 (en) 2024-08-13
AU2020308906A1 (en) 2022-02-03
EP3990656B1 (en) 2026-04-22
EP3990656A4 (en) 2023-12-06
GB2603294A (en) 2022-08-03

Similar Documents

Publication Publication Date Title
MX2023010970A (es) Metodos de clasificacion y tratamiento de pacientes.
Sarto et al. Effects of short‐term unloading and active recovery on human motor unit properties, neuromuscular junction transmission and transcriptomic profile
Quintana et al. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3‐like 1 and neurofilament light chain
Drennan et al. A comparison of the universal TOR Guideline to the absence of prehospital ROSC and duration of resuscitation in predicting futility from out-of-hospital cardiac arrest
Kimball et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
Mitchell et al. The effect of B cell depletion therapy on anti‐TSH receptor antibodies and clinical outcome in glucocorticoid‐refractory Graves' orbitopathy
Kampmann et al. Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid‐associated orbitopathy: a prospective study
Asady et al. Cholinergic urticaria patients of different age groups have distinct features
Foocharoen et al. Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma
MX2018003376A (es) Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
EP3761034A3 (en) Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
ZA202106769B (en) Treatment of ciliopathies
EA201892542A1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
WO2023052222A3 (en) System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation
Chaabna et al. Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence?
Levenson et al. Social rhythm disrupting events increase the risk of recurrence among individuals with bipolar disorder
Shiramizu et al. Impact of persistent minimal residual disease post‐consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report
Raham Influence of malaria endemicity and tuberculosis prevalence on COVID-19 mortality
White et al. Coprevalence of tremor with spasmodic dysphonia: a case‐control study
MX2023002446A (es) Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf.
Turner et al. IgE‐sensitization predicts threshold but not anaphylaxis during oral food challenges to cow's milk
Evoli et al. Italian recommendations for Lambert–Eaton myasthenic syndrome (LEMS) management
EA202192176A1 (ru) Нарушения, опосредованные интерфероном i типа